



For Immediate Release

Symic to Present at the 23rd Annual BioCentury NewsMakers in the Biotech Industry Conference

SAN FRANCISCO, Aug. 29, 2016 – Symic, a clinical stage biotherapeutics company developing therapies inspired by naturally occurring molecules of the extracellular matrix, today announced that Ken Horne, Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference.

Conference details:

Date: Friday, Sept. 9, 2016

Time: 11:30 a.m. EDT

Location: Millennium Broadway Hotel, New York

About Symic

Symic Bio is a clinical stage biotherapeutics company developing therapies inspired by proteoglycans, naturally occurring macromolecules of the extracellular matrix (ECM). The structural and regulatory properties of proteoglycans have potential applications in a wide variety of disease states. Symic Bio currently has two clinical candidates, one to address complications of vascular injury and one for disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis and oncology.

For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio/ or follow on Twitter at www.twitter.com/symicbio.

Media Contacts

David Schull or Rich Allan

Russo Partners, LLC

(212) 845-4271

(646) 942-5588

david.schull@russopartnersllc.com

rich.allan@russopartnersllc.com

###